Showing results (411-420 of 421) with videos related to
Sort By:
Pageof 43
The Journal of Clinical Investigation|October 6, 2015
Proteinase 3 on apoptotic cells disrupts immune silencing in autoimmune vasculitisArnaud Millet, Katherine R Martin, Francis Bonnefoy, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2018
Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical TrialsD Ross Camidge, Dong-Wan Kim, Marcello Tiseo, et al.Annals of the Rheumatic Diseases|May 20, 2022
Induced antibodies directed to the angiotensin receptor type 1 provoke skin and lung inflammation, dermal fibrosis and act species overarchingXiaoyang Yue, Junping Yin, Xiaoqing Wang, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 23, 2019
Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA TrialRudolf M Huber, Karin H Hansen, Luis Paz-Ares Rodríguez, et al.Frontiers in Immunology|April 25, 2018
Pathogenetic and Clinical Aspects of Anti-Neutrophil Cytoplasmic Autoantibody-Associated VasculitidesPeter Lamprecht, Anja Kerstein, Sebastian Klapa, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2017
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II TrialDong-Wan Kim, Marcello Tiseo, Myung-Ju Ahn, et al.Scientific Reports|September 28, 2020
Ambrisentan, an endothelin receptor type A-selective antagonist, inhibits cancer cell migration, invasion, and metastasisLucy Kappes, Ruba L Amer, Sabine Sommerlatte, et al.Autoimmunity Reviews|November 27, 2022
Autoimmune pre-diseaseKatja Bieber, Jennifer E Hundt, Xinhua Yu, et al.The New England Journal of Medicine|October 4, 2018
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung CancerD Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, et al.Hepatology (Baltimore, Md.)|March 1, 1981
Distal splenorenal shunt vs. portal-systemic shunt: current status of a controlled trialH O Conn, R H Resnick, N D Grace, et al.Pageof 43